Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.
about
Novel drugs targeting hypertension revisitedTargeting soluble guanylate cyclase for the treatment of pulmonary hypertension.Gas what: NO is not the only answer to sexual function.How full is our antihypertensives pipeline?Systems biology of HBOC-induced vasoconstriction.Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.The chemistry and biology of soluble guanylate cyclase stimulators and activators.Small molecule and peptide therapies for chronic heart failure: a patent review (2011 - 2014).Non-nitric oxide based metallovasodilators: synthesis, reactivity and biological studies.Insight into the rescue of oxidized soluble guanylate cyclase by the activator cinaciguat.Soluble guanylyl cyclase-activated cyclic GMP-dependent protein kinase inhibits arterial smooth muscle cell migration independent of VASP-serine 239 phosphorylation.Riociguat: PATENT-1 Study.Cinnamyl alcohol attenuates vasoconstriction by activation of K⁺ channels via NO-cGMP-protein kinase G pathway and inhibition of Rho-kinase.Activation of soluble guanylyl cyclase by BAY 58-2667 improves bladder function in cyclophosphamide-induced cystitis in mice.Vasodilatory effects of cinnamic acid via the nitric oxide-cGMP-PKG pathway in rat thoracic aorta.The Regulation of Pulmonary Vascular Tone by Neuropeptides and the Implications for Pulmonary Hypertension
P2860
Q34139743-675A53C5-F4E5-4AAD-88D9-BBD83BACD2E2Q34179857-E671D561-9F2A-4FF3-9EC3-A410533182ACQ35204833-04B36E39-8982-45B9-B0E9-C76011B84BE4Q35770676-88563E8F-6175-4BC4-87F1-088B5057F33CQ37897234-8CF22CF2-DE0E-4299-978D-9309386F5C01Q38000562-C79A1FA3-8274-4797-B47A-AC9C8AB69D31Q38130465-2DF1E6B7-A9CF-42C4-AB59-00B693B33CF3Q38546917-3209CF41-94DE-47B7-A829-323697F85AE7Q38856565-C918263A-7561-4A73-ABC2-70F237E0188EQ41770411-0D85C149-2255-46DF-AE40-491CADC61782Q41869044-91DF5607-7DCC-4D4D-AD53-717595EA743BQ41980644-D7A57344-7B1E-4A3B-96EA-6A5141BCE37CQ42555672-14BCF70C-3407-4E49-BC64-4E8CFF0FF4EAQ46556756-8617C56C-6357-4B74-865B-5DF1BB7B45B2Q50248443-F6C73862-DDA6-4539-B3A6-01968670B4BAQ57167791-0A58452D-B7C3-4A22-A9CD-877506CB061A
P2860
Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.
@ast
Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.
@en
Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.
@nl
type
label
Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.
@ast
Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.
@en
Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.
@nl
prefLabel
Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.
@ast
Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.
@en
Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.
@nl
P2860
P1476
Heme-dependent and independent soluble guanylate cyclase activators and vasodilation
@en
P2093
R Clinton Webb
P2860
P304
P356
10.1097/FJC.0B013E3181EB4E75
P407
P577
2010-09-01T00:00:00Z